CLPH-251

CLPH-251 is an investigational cell therapy product developed by Cellphire Therapeutics. It is part of a freeze-dried platelet-derived hemostat platform and is designed to address bleeding disorders and acute hemorrhagic conditions. The drug aims to provide an off-the-shelf alternative to autologous platelet-rich plasma (PRP), offering consistent quality and composition for hemostatic applications. Its primary therapeutic focus includes brain hemorrhage—a leading cause of mortality and disability in individuals under 40—and potentially other nervous system or cardiovascular diseases related to bleeding or trauma. As of now, CLPH-251 has not entered clinical trials but remains in preclinical development[1][2][3][4].

Other names

freeze-dried platelet hemostatFPH